Cargando…
Clinical evidence and insights supporting the use of avelumab first‐line maintenance treatment in patients with advanced urothelial carcinoma in the Asia‐Pacific region
Until recently, international and Asia‐specific guidelines for advanced urothelial carcinoma (UC) recommended first‐line (1L) platinum‐based chemotherapy, followed by second‐line (2L) anti‐PD‐1 or anti‐PD‐L1 immune checkpoint inhibitor (ICI) therapy where possible, or 1L ICI therapy in cisplatin‐ine...
Autores principales: | Eto, Masatoshi, Lee, Jae‐Lyun, Chang, Yen‐Hwa, Gao, Seasea, Singh, Manmohan, Gurney, Howard |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9542411/ https://www.ncbi.nlm.nih.gov/pubmed/35238147 http://dx.doi.org/10.1111/ajco.13765 |
Ejemplares similares
-
Avelumab first-line maintenance plus best supportive care (BSC) vs BSC alone for advanced urothelial carcinoma: JAVELIN Bladder 100 Japanese subgroup analysis
por: Tomita, Yoshihiko, et al.
Publicado: (2022) -
Avelumab First-Line Maintenance for Advanced Urothelial Carcinoma: Results From the JAVELIN Bladder 100 Trial After ≥2 Years of Follow-Up
por: Powles, Thomas, et al.
Publicado: (2023) -
Avelumab first-line maintenance treatment for advanced urothelial carcinoma: review of evidence to guide clinical practice
por: Grivas, P., et al.
Publicado: (2023) -
Cost-Effectiveness of Avelumab Maintenance Therapy Plus Best Supportive Care vs. Best Supportive Care Alone for Advanced or Metastatic Urothelial Carcinoma
por: Xie, Qian, et al.
Publicado: (2022) -
Corrigendum: Cost-effectiveness of avelumab maintenance therapy plus best supportive care vs. best supportive care alone for advanced or metastatic urothelial carcinoma
por: Xie, Qian, et al.
Publicado: (2022)